Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Family presence during resuscitation of a child remains controversial and disagreement persists about whether and when potential benefits outweigh risks.
AMA J Ethics. 2018;20(5):507-512. doi:
10.1001/journalofethics.2018.20.5.sect1-1805.
Frances Grimstad, MD, MS and Elizabeth Boskey, PhD, MPH, MSSW, LICSW
Gender-affirming surgery for teens is growing as a field. Norms about who should be involved, to what extent, and for which health decisions are still evolving.
AMA J Ethics. 2020;22(5):E452-457. doi:
10.1001/amajethics.2020.452.